Literature DB >> 15053048

A case of lactic acidosis caused by stavudine in an AIDS patient.

Byoung Chul Cho1, Sang Hoon Han, Suk Hoon Choi, Jun Yong Choi, Kyung Hee Chang, Young Goo Song, June Myung Kim.   

Abstract

Nucleoside reverse transcriptase inhibitors (NRTIs), which are used for the treatment of human immunodeficiency virus (HIV) infection have been associated with a wide spectrum of clinical manifestations, including hepatic steatosis, lipodystrophy, myopathy, and lactic acidosis. Such adverse effects are postulated to result from the inhibition of mitochondrial DNA gamma polymerase, which causes the depletion of mitochondrial DNA and eventual the disruption of oxidative phosphorylation. Although cases of severe decompensated lactic acidosis are rare, this syndrome is associated with a high mortality rate. We report upon the first Korean case, of severe lactic acidosis in an acquired immunodeficiency syndrome (AIDS) patient receiving stavudine, an anti-HIV drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15053048      PMCID: PMC4531542          DOI: 10.3904/kjim.2004.19.1.66

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  17 in total

1.  L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues.

Authors:  Y E Claessens; A Cariou; J D Chiche; G Dauriat; J F Dhainaut
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

2.  Riboflavine and severe lactic acidosis.

Authors:  R Luzzati; P Del Bravo; G Di Perri; A Luzzani; E Concia
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

3.  Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors.

Authors:  Fenneke C P Frerichs; Koert P Dingemans; Kees Brinkman
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

4.  Miller Fisher variant of Guillain-Barré syndrome associated with lactic acidosis and stavudine therapy.

Authors:  Sanjiv S Shah; Tomas Rodriguez; Joseph P McGowan
Journal:  Clin Infect Dis       Date:  2003-05-09       Impact factor: 9.079

5.  Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.

Authors:  M John; C B Moore; I R James; D Nolan; R P Upton; E J McKinnon; S A Mallal
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

6.  Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.

Authors:  M E Coghlan; J P Sommadossi; N C Jhala; W J Many; M S Saag; V A Johnson
Journal:  Clin Infect Dis       Date:  2001-10-24       Impact factor: 9.079

7.  Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  K Boubaker; M Flepp; P Sudre; H Furrer; A Haensel; B Hirschel; K Boggian; J P Chave; E Bernasconi; M Egger; M Opravil; M Rickenbach; P Francioli; A Telenti
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

8.  Emerging role of riboflavin in the treatment of nucleoside analogue-induced type B lactic acidosis.

Authors:  S D Dalton; A R Rahimi
Journal:  AIDS Patient Care STDS       Date:  2001-12       Impact factor: 5.078

9.  Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy.

Authors:  Y Gérard; L Maulin; Y Yazdanpanah; X De La Tribonnière; C Amiel; C A Maurage; S Robin; B Sablonnière; C Dhennain; Y Mouton
Journal:  AIDS       Date:  2000-12-01       Impact factor: 4.177

10.  Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

Authors:  P Chariot; I Drogou; I de Lacroix-Szmania; M C Eliezer-Vanerot; B Chazaud; A Lombès; A Schaeffer; E S Zafrani
Journal:  J Hepatol       Date:  1999-01       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.